Tryton I, First-In-Man (FIM) study: six month clinical and angiographic outcome, analysis with new quantitative coronary angiography dedicated for bifurcation lesions

EuroInterv.2008;3:546-552.

Yoshinobu Onuma1, MD; Ralf Müller2, MD; Steve Ramcharitar1, MRCP DPhil; Robert-Jan M. van Geuns1, MD, PhD; Yves Louvard3, MD; Marie-Angèle Morel4, BSc; Marie-Claude Morice3, MD; Richard Davis5, MSc; Aaron V. Kaplan6, MD; Thierry Lefèvre3, MD; Eberhard Grube2, MD; Patrick Serruys1*, MD, PhD

1. Thoraxcenter, Erasmus MC, Rotterdam, The Netherlands; 2. Helios Heart Center, Siegburg, Germany; 3. Institut Cardiovasculaire Paris Sud, Massy, France; 4. Cardialysis B.V., The Netherlands; 5. Tryton Medical, Inc. Newton, MA, USA; 6. Dartmouth Medical

Aim: To report clinical and angiographic follow-up at 6 months after implantation of the Tryton Side-Branch Stent™ dedicated to bifurcation, in conjunction with standard workhorse drug-elut

Forgot your password?

No account yet? Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

bifurcation stentqcabare metal stent

Share on Facebook Share on Twitter Share on Linkedin

Tryton I, First-In-Man (FIM) study: six month clinical and angiographic outcome, analysis with new quantitative coronary angiography dedicated for bifurcation lesions

Read next article

Latest news

Coronary

Valvular disease

Heart failure

Peripheral

Hypertension

Stroke